Venus gets marketing authorisation from Myanmar for antibiotic

Pharma major Venus Remedies Ltd today announced to get marketing authorisation for its antibiotic 'Elores' from Myanmar and said it plans to roll out this drug by April this year.
"This marketing authorisation will help us making big strides in Southeast Asia. The size of Myanmar's pharmaceutical market is USD 400 million and the country imports 85-90 per cent of its pharma products.
"We are looking to capture a sizeable chunk of the antibiotics market in Myanmar with Elores," company's CMD Pawan Chaudhary said in a statement.
Panchkula based drug major has already received patents for Elores from 46 countries.

Besides, the registration procedure of this product is in advanced stages in 13 European Union member-nations and 15 other countries, including South Korea, South Africa and Saudi Arabia, it said.
Elores is effective against serious multidrug-resistant hospital-acquired infections involving metallo-beta-lactamase and carbapenem-resistant strains of bacteria.
The company said it has spent USD 10 million on product's R&D.
Headquartered at Panchkula in Haryana, the company has three manufacturing units, in Panchkula, Baddi (HP) and Werne (Germany) and 11 overseas marketing offices, including a presence in the US and Germany.